… IBD (52 with Crohn's disease and 22 with ulcerative colitis or … exposure–response relationship,
clinical outcomes were evaluated by trough levels, clearance and vedolizumab exposure…

… Vedolizumab is the first biologic agent approved for the treatment of both inflammatory bowel
diseases (IBD), UC and Crohn’s disease (… with vedolizumab, we excluded patients exposed …

… Vedolizumab (VDZ) is an anti-α4β7 integrin monoclonal antibody approved for the treatment
of Crohn disease (CD) and ulcerative colitis (UC) in patients 18 years of age and older (1,2) …

… We excluded patients with ostomies, history of a colectomy or those with previous
exposure to vedolizumab, and patients with no evidence of baseline active endoscopic …

… on vedolizumab in paediatric inflammatory bowel disease [… In conclusion, vedolizumab
serum exposure increased in an … population, and vedolizumab exposure, clinical response and …

… a diagnosis of inflammatory bowel disease [IBD] unclassified… With a median disease duration
of 14.7 [interquartile range, … previously been exposed to anti-TNF or vedolizumab therapy […

… , which may affect an association of exposure and response, and may have impacted …
individual patient level synthesis, pooled exposure-response analysis and development of …

… Inflammatory bowel diseases (IBD), encompassing Crohn’s disease (CD) and … extra dose
of vedolizumab did not have a longer disease duration, greater exposure to biological therapies…

… Data from trials of vedolizumab for inflammatory bowel disease and from real-world studies
suggest an exposure-response relationship, such that vedolizumab trough levels may predict …

… The control group included 88 pregnancies exposed to anti-TNF in 76 women with … exposed
to >2 anti-TNF agents was significantly increased among the ustekinumab and vedolizumab …